Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Challenges With Diagnosis of ITP

February 16th 2022

Experts discuss lack of consensus in diagnosis of ITP and challenges physicians face.

ITP Treatment in Pregnancy

February 16th 2022

ITP experts share considerations in the treatment of pregnant patients with ITP.

Gerds Takes a Closer Look at Treatment Sequencing in Hematologic Malignancies

February 16th 2022

Aaron T. Gerds, MD, MS, discusses the use of TKIs, targeted agents, JAK inhibitors, and cellular therapy in hematologic malignancies.

An Overview of CML Treatment Toxicities

February 16th 2022

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

Chronic Myeloid Leukemia: Asciminib’s Toxicity Profile

February 16th 2022

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

February 14th 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

February 14th 2022

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Updates From ASH 2021 for Belantamab-based Combinations in Myeloma

February 11th 2022

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Optimizing the Sequencing of Therapy in Follicular Lymphoma

February 11th 2022

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

February 11th 2022

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies

February 10th 2022

We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.

Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma

February 10th 2022

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Safety With CAR-T Therapies in R/R DLBCL

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 10th 2022

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Treatment of Older Patients With ITP

February 9th 2022

Drs Bussel, Piatek and Kessler discuss treatment of older patients with ITP.

Fostamatinib in Immune Thrombocytopenia

February 9th 2022

Dr Bussel discusses the use of fostamatinib in patients who have progressed on TPO agents.

Prior Rituximab Reduces the Effectiveness of COVID-19 Vaccination in Lymphoma

February 9th 2022

Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.

CML Management: Personal Experience With Asciminib

February 9th 2022

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia

February 9th 2022

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.